XENE - Xenon Pharmaceuticals Inc Net Margin

XENE (Xenon Pharmaceuticals) - company brandmark

Xenon Pharmaceuticals competes in the neuropharmaceutical sector, leveraging patent protection for ion channels. The company is developing a therapy system for complex epileptic disorders. The business is currently focused on independently bringing products to market, as evidenced by the net profit margin chart. This metric is recorded at 0.00, clearly demonstrating current capital management efficiency and the profitability of each unit of revenue.

Xenon Corp (XENE) - Net Sales Margin from 07/04/2022 to 11/20/2026

Analytical breakdowns for Xenon Pharmaceuticals

- market value and analyst target forecast:
Initial company analysis:Xenon Pharmaceuticals, XENE
Flagship merchandise of Xenon Corp

Sales margin measures the share of net profit in every dollar of revenue, determining the actual efficiency of converting operating income into shareholder equity. An analysis of relative net profit from sales allows for an assessment of the future patent rent potential of Xenon Pharmaceuticals (XENE), where the chronic nature of epilepsy therapy guarantees stable demand and long-term monetization of developed drugs.

Competitor analysis for Xenon Pharmaceuticals

BIIB: Net Sales Margin|Net Margin Neurocrine Biosciences Inc (NBIX)|RGC (Regencell Corp) - Net Sales Margin|AXSM: Net Profit Rate|Net Margin acadia-pharm.com (ACAD)|Net Sales Margin vikingtherapeutics.com (VKTX)|Net Margin Supernus SUPN|Net Profit Rate CPRX|denalitherapeutics.com - Net Sales Margin|Company Sales Margin Harmony Pharma HRMY|BHVN: Net Sales Margin|Net Margin Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI (Trevi Therapeutics Inc) - Net Sales Margin|Net Return on Sales PRAX (Praxis Medicines)|Net Margin Anavex Life Sciences (AVXL)|Net Margin CBLL (CeriBell EEG)|Net Sales Margin PRTA (Prothena Corp)|alector.com (ALEC) - Net Margin|ANNX: Return on Sales by Net Profit|Net Margin Omeros|NGNE: Net Sales Margin|Return on Sales by Net Profit AC Immune|Return on Sales by Net Profit VYGR|Net Return on Sales NMRA (neumoratx.com)|Return on Sales by Net Profit SCLX (Scilex Holding Company, Inc.)|Net Margin TVGN (Tevogen Bio)|Net Margin Alpha Cognition ACOG|CGTX - Return on Sales by Net Profit|IKT - Net Margin|SAVA: Net Margin|Assertio Therapeutics (ASRT) - Net Margin|Net Margin Coya Therapeutics Inc (COYA)|Net Margin Vistagen|Net Return on Sales OVID (ovidrx.com)|Net Margin Acumen Pharmaceuticals, Inc. (ABOS)|CRVO - Net Margin|Alterity Therapeutics Ltd. - Return on Sales by Net Profit|CLNN - Return on Sales by Net Profit|PEPG - Net Margin|Company Sales Margin jupiterneurosciences.com JUNS|Relmada Therapeutics (RLMD) - Net Margin|ANVS (Annovis Bio, Inc.) - Net Margin|Net Margin gracetx.com|Net Sales Margin Firefly Neuroscience, Inc.|Net Margin ANEW Medical (KLTO)|NRSN - Net Margin|Net Sales Margin RVPH (Reviva Pharmaceuticals Holdings Inc.)|Company Net Profitability MTVA (metaviatx.com)|NeurAxis Inc. - Net Sales Margin|Company Sales Margin heliusmedical.com HSDT|PASG: Net Sales Margin|Neuphoria - Net Profit Rate|Return on Sales by Net Profit NERV|ATHA: Net Profit Rate|Net Margin Addex Therapeutics Ltd (ADXN)|ALZN (Alzamend Neuro Inc.) - Net Profit Rate|Net Sales Margin CYCN (cyclerion.com)|Net Profitability Margin Protagenic|KTTA: Return on Sales by Net Profit|Net Profit Rate CRGT (cortigent.com)|ATXI: Net Sales Margin|BCLI (BrainStorm Cell Therapeutics) - Net Margin|CARA (Cara Therapeutics Inc.) - Net Sales Margin|Net Margin CHRO|Return on Sales by Net Profit ELYM (Eliem Therapeutics)|Net Margin ITCI (Intra-Cellular Therapies Inc.)|Net Sales Margin LBPH (Longboard Pharma)|Net Sales Margin Marinus Pharmaceuticals Inc MRNS|NKGen Biotech Corp - Net Sales Margin|Net Profit Rate NRBO (NeuroBo Pharma)|SAGE (Sage Therapeutics, Inc) - Return on Sales by Net Profit|Net Return on Sales SNPX|Return on Sales by Net Profit TRVN|Net Margin VIGL|Net Sales Margin WENA|Company Sales Margin Cerevel